TADCLOT- a Double Blind Randomized Controlled Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2200 participants.

Also called NCT06318481

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06318481
Other papers using this trial's data
  • Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial Journal of the American College of Cardiology, 2025-12-09 DOI, PubMed 40892606

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06318481. Randomized; triple masking; primary purpose treatment. Start 2024-02-19 (actual); primary completion 2025-02-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TADCLOT- a Double Blind Randomized Controlled Trial
Acronym
TADCLOT
Condition
Stent Thrombosis
Condition
Myocardial Infarction, Acute
Intervention (Drug)
Ticagrelor 90 MG
Intervention (Drug)
Clopidogrel
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan (class: other)
Collaborator
PharmEvo Pvt Ltd (class: industry)

Record details

Record id
cardio:ct-nct06318481
Content hash
a50c4adb02b9da2dd317582dcaae45596bb8ef55e7e121e36ff1db8a9878f843